Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 8/20 | 0.37 |
| ▸ | SCN1A | P35498 | 4/20 | 0.37 |
| ▸ | DNM1L | O00429 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3012253 | 0.92 | SCN8A (0.36) | SCN8ASCN1ADNM1LGBA1HTR2A | |
| SCHEMBL3007833 | 0.92 | LMNA (0.37) | SCN8ASCN1ADNM1LLMNAL3MBTL1 | |
| SCHEMBL3007012 | 0.91 | GBA1 (0.38) | DNM1LLMNAGBA1HTR2AMAPT | |
| SCHEMBL3018787 | 0.90 | RAB9A (0.39) | DNM1LGBA1HTR2AMAPT | |
| SCHEMBL3010771 | 0.90 | HTR2A (0.34) | LMNAL3MBTL1HTR2A | |
| SCHEMBL3007199 | 0.90 | MAPT (0.39) | LMNAGBA1MAPTMAPK1 | |
| SCHEMBL3016660 | 0.90 | GBA1 (0.38) | SCN8ASCN1ADNM1LLMNAL3MBTL1 | |
| SCHEMBL3020188 | 0.90 | DNM1L (0.37) | SCN8ASCN1ADNM1LGBA1HTR2A | |
| SCHEMBL2997684 | 0.90 | GBA1 (0.43) | DNM1LGBA1HTR2AMAPT | |
| SCHEMBL3015155 | 0.90 | HTR2A (0.41) | DNM1LLMNAL3MBTL1GBA1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | SMN1; SMN2, HTT, SNCA | SCN8A 2162/4885SCN1A 185/4885DNM1L 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.